EW vs SYK
EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions. SYK: A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve over 150 million patients annually across 61 countries.
Side-by-side fundamentals
| Metric | EW | SYK | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $87.27 | $316.44 | |
| Market cap as of 2026-07-16 | $50.9B | $121.3B | |
| P/E as of 2026-07-16 | 46.42 | 36.35 | SYK lower |
| PEG as of 2026-07-16 | 2.13 | 3.29 | EW lower |
| Net margin as of 2026-07-16 | +17.4% | +13.2% | EW higher |
| Gross margin as of 2026-07-16 | +77.9% | +64.2% | EW higher |
| Operating margin as of 2026-07-16 | +17.1% | +19.7% | SYK higher |
| ROE as of 2026-07-16 | +10.6% | +15.1% | SYK higher |
| ROA as of 2026-07-16 | +8.2% | +7.1% | EW higher |
| Debt / equity as of 2026-07-16 | 0.06 | 0.64 | EW lower |
| Revenue growth (YoY) as of 2026-07-16 | +13.8% | +8.8% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +10.8% | Tie |
| Dividend yield as of 2026-07-16 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-16 | 0.83 | 0.78 | |
| 1-year return as of 2026-07-15 close | +15.1% | -19.0% | EW higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.